Korea Research Institute of Chemical Technology

Korea Research Institute of Bioscience and Biotechnology

Cj Corporation

Jeil Pharm. Co., Ltd.

Hanall Biopharma Co., Ltd.

Handok Pharmaceuticals Co., Ltd.

Kwang-Rok Kim

Won Hoon Jung

Sang Dal Rhee

Hyae Gyeong Cheon

Jin Hee Ahn

Sung Soo Kim

Jeong-Hyung Lee

Sung-eun Yoo

Seung Jun Kim

Jae Mok Lee

Seung Kyu Kang

Jong Min Kim

Sung Dae Park

Sung-Don Yang

Nam Gee Kim

Ki Young Kim

Sung Wuk Kim

Sung Soo Jun

Hyoung Rae Kim

Jong-Cheol Lee

Ge Hyeong Lee

Seog Beom Song

Myung-Ae Bae

Jung Ki Kim

Jin Sook Song

Kil Woong Mo

Soon Ji Kwon

Bo Gan Song

Sun Mee Kim

Koun Ho Lee

H S Pagire

Sun Chul Huh

Jang Hyuk Lee

Min Jung Seo

Jaesung No

Hye Jung Kang

Hyun Jung Kwak

Bum Suk Son

The present invention relates to a beta-alanine derivative, pharmaceutically acceptable salts thereof, and a pharmaceutical composition including the same as an active ingredient. The novel beta-alanine derivative and pharmaceutically acceptable salts thereof according to the present invention may effectively inhibit the activity of DGAT1, which is an enzyme serving as a catalyst in the final step of the synthesis of neutral lipids, to thereby be effectively used as a pharmaceutical composition for preventing or treating various lipid metabolism-related disorders selected from the group consisting of obesity, dyslipidemia, fatty liver, insulin resistance syndrome, and hepatitis.

Beta-alanine derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical composition comprising same as active ingredient

Disclosed herein are a 1,3,5-triazine-2,4,6-triamine compound or a pharmaceutically acceptable salt thereof, a preparation method thereof, and a composition for preventing or treating metabolic syndromes, diabetes, or cancers with deletion of P53 gene, which comprises the same.

1,3,5-triazine-2,4,6-triamine compound or pharmaceutical acceptable salt thereof, and pharmaceutical composition comprising the same

The inventive indene derivatives of formula (I) are capable of selectively modulating the activities of peroxisome proliferator activated receptors (PPARs), causing no adverse side effects, and thus, they are useful for the treatment and prevention of disorders modulated by PPARs, i.e., metabolic syndromes such as diabetes, obesity, arteriosclerosis, hyperlipidemia, hyperinsulinism and hypertension, inflammatory diseases such as osteoporosis, liver cirrhosis and asthma, and cancer.

Indene derivatives and process for the preparation thereof

An indene derivative for selectively modulating the activities of peroxisome proliferator activated receptors (PPARs) having the following formula (I): wherein, or phenyl; being each unsubstituted or substituted with one or more substituents selected from the group consisting of halogen, CN, NH, NO, OR, phenyloxy, Calkyl, and Ccycloalkyl; and

The present invention relates to a 5-(1,3-diaryl-1H-pyrazol-4-ylmethylene)-thiazolidine-2,4-dione derivative or its pharmaceutically acceptable salts thereof, a method for preparing the same and an anticancer agent composition comprising the same as an active ingredient.

5-(1,3-Diaryl-1H-pyrazol-4-ylmethylene)-thiazolidine,2,4-dione derivatives useful as anticancer agent

Growing community of inventors

Daejeon, South Korea

Kwang-Rok Kim